Stock speculation is based on the Jin Kirin analyst Research report, authoritative, professional, timely and comprehensive, to help you tap potential theme opportunities.Arcadeuppacman!
After the share prices in the secondary market continued to weaken, a number of new third board companies unveiled share buyback plans, some of which had planned to list on the North Stock Exchange, and Hongyue Flower and other companies once joined the IPO queue of the North Stock Exchange.
The repurchase price caps of some companies far exceed the market share price. For example, the repurchase price of Jinbaihui, which will be bought back again in the near future, does not exceed 6 yuan per share, and the stock price has recently fallen below 2 yuan.
The buyback plan of two IPO concept stocks of the Beijing Stock Exchange
The new third board companies have frequently put forward share buyback plans, and some companies have declared for listing on the North Stock Exchange.
Hongyue Flower said that in order to promote the long-term and healthy development of the company, enhance investor confidence in the future, safeguard the interests of investors, and improve the company's operational efficiency indicators, on the basis of comprehensive consideration of the company's operating situation, financial situation and future profitability, the company plans to use its own funds to buy back the company's shares.
It is worth mentioning that Hongyue Flower buyback company shares, used to write off and reduce the registered capital. The company determined that the repurchase price was 8.Arcadeuppacman.5 yuan per share. The board of directors of the company considers the adoption of the share repurchase plan, and there is an average trading price in the 60 trading days before the adoption of the share repurchase plan (excluding the date of suspension), the average trading price is 7.63 yuan, and the proposed repurchase price is not lower than the above price and not higher than 200% of the above price.
According to Hongyue Flower's share buyback plan, the company intends to buy back no more than 3 million shares, accounting for no more than 5.17% of the company's total share capital. It is estimated that the total amount of funds to be repurchased will not exceed 25.5 million yuan.
According to the company, at the expiration of the offer period, if the number of shares that the shareholders agree to accept the buyback offer (referred to as the "pre-accepted offer") exceeds the number of shares scheduled to be repurchased, the company will buy back the shares pre-received by the shareholders according to the same proportion. If the number of shares pre-offered by the shareholders is less than the number of shares scheduled to be repurchased, the company will buy back all the shares pre-accepted by the shareholders.
Hongsen Pharmaceutical said that in order to promote the long-term and healthy development of the company, enhance investor confidence in the future, safeguard the interests of investors, and improve the company's operational efficiency indicators, on the basis of comprehensive consideration of the company's operating situation, financial situation and future profitability, the company plans to use its own funds to buy back the company's shares and reduce the company's registered capital.
According to the share buyback plan disclosed by Hongsen Pharmaceutical Co., Ltd., the repurchase price is determined to be 13.28 yuan per share. According to reports, since the company was listed and publicly transferred in the national share transfer system for small and medium-sized enterprises on July 7, 2022, the company's stock has not been traded in the secondary market, there is no trading price, and the secondary market trading price of the company's stock has no reference significance.
The company intends to buy back 1 million shares, accounting for no more than 1.01% of the company's current total share capital. It is estimated that the total amount of funds to be repurchased will not exceed 13.28 million yuan. According to the plan, at the expiration of the offer period, if the number of shares that the shareholders agree to accept the repurchase offer exceeds the number of shares scheduled to be repurchased, the company will buy back the shares pre-received by the shareholders according to the same proportion. If the number of shares offered by the shareholders is less than the number of shares scheduled to be repurchased, the company will buy back all the shares pre-received by the shareholders.
It is worth mentioning that both Hongyue Flower and Hongsen Pharmaceutical have declared for listing on the North Exchange and were accepted. Hongyue Flower withdrew its listing application and terminated the listing examination on the North Exchange in September 2023. Hongsen Pharmaceutical also withdrew its listing application and formally terminated the listing examination on the North Stock Exchange on April 30, 2024.
These new third board companies implement buybacks.
A number of new third board companies have implemented buybacks in the secondary market, and the repurchase price caps planned by some companies are much higher than their recent share prices.
Shindao Technology buys back in the secondary market. According to the share repurchase plan disclosed by the company on March 29th, the number of shares to be repurchased this time is not less than 3.6023 million shares and not more than 4.8031 million shares, accounting for 1.5% of the company's total share capital. According to the number of shares to be repurchased and the upper limit of the proposed repurchase price, the total amount of repurchase funds is expected to not exceed 28.8186 million yuan. The repurchase of the company's shares is used to implement equity incentives.
Xindao Technology determined that the repurchase price did not exceed 6.00 yuan per share, and the company carried out its first repurchase on May 6. On May 6, the company repurchased 40,000 shares of the company in a market-making manner through a special securities account for repurchase shares, accounting for 0.02% of the total share capital of the company. It accounts for 0.83% of the upper limit of the proposed repurchase quantity, with the highest transaction price of 3.98 yuan per share and the lowest transaction price of 3.93 yuan per share.
Recently, Xindao Technology has continued to implement repurchase. As of May 22, 2024, the company has repurchased 2.588 million shares of the company through a special securities account for share repurchase, accounting for 1.08% of the total share capital of the company and 53.88% of the upper limit of the proposed buyback quantity. The highest transaction price is 4.01 yuan per share, and the lowest transaction price is 3.93 yuan per share. The total amount paid is 10.3243 million yuan (excluding stamp duty, commission and other transaction fees), accounting for 38.73% of the total amount of funds to be repurchased by the company.
Jinbaihui has continued to implement buybacks since the beginning of this year. According to the share repurchase plan disclosed by the company in December 2023, the company intends to use its own funds to repurchase the company's shares for write-off and reduce the registered capital. The repurchase price of the company does not exceed 6 yuan per share, and the number of shares to be repurchased is not less than 3 million shares and not more than 4.5 million shares, accounting for 5.77% of the company's total share capital. 8.65%. According to the number of shares to be repurchased and the upper limit of the proposed repurchase price, it is estimated that the total amount of repurchase funds will not exceed 27 million yuan, and the capital will come from its own funds.
Jinbaihui disclosed that as of April 30, the company had repurchased 1.19 million shares of the company by collective bidding through a special securities account for repurchasing shares, with an average transaction price of 3.442 yuan per share. The total amount is 4.0962 million yuan (excluding stamp duty, commission and other transaction fees), and the number of repurchased shares accounts for 2.29% of the total share capital of the company, accounting for 26.44% of the upper limit of the number of shares to be repurchased.
Golden Parkway plans to continue its buyback in the near future, with the company announcing that it will do so from May 29 to June 4. In the secondary market, the share price has weakened again recently, with the share price below 2 yuan, closing at 1.95 yuan on May 20.
Weimen Pharmaceutical has continued to implement buybacks this year, and has recently completed its buyback plan. The company's share repurchase period begins on December 15, 2023 and ends on May 22, 2024. The proportion of the actual repurchase quantity to the upper limit of the proposed repurchase quantity is 99.57%, which has exceeded the lower limit of the repurchase scale disclosed in the repurchase plan.
The company has purchased a total of 2.29 million shares of the company through collective bidding through a special securities account for share repurchase, with a total amount of 7.5904 million yuan (excluding transaction fees such as stamp duty and commissions). The proportion of this repurchase in the company's total share capital is 1.82%, accounting for 99.57% of the total number of shares to be repurchased. The highest transaction price is 3.74 yuan/share, and the lowest transaction price is 2.99 yuan/share.
Xindao Technology, Jinbaihui, and Weimen Pharmaceutical also planned to list on the Beijing Stock Exchange and once joined the IPO queue of the Beijing Stock Exchange. This is the second time Xindao Technology has launched a repurchase after terminating the listing review of the Beijing Stock Exchange.